Sept. 17, 2025
| Today’s news and insights for biopharma leaders
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.
|
Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.
|
A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.
|
News roundup
Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”
|
UPDATED
New startup Kalexo Bio launched with rights to an RNA drug for heart disease that came via a potentially $1 billion deal with China's Mabwell Bioscience.
|
From Our Library
Playbook
Custom content for PharmaForceIQ
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by 10x Genomics
|
Trendline
Supported by ELEGEN
|
Playbook
Custom content for Evaluate
|
View all resources
What We’re Reading
| 
